| 摘要 |
The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III).;;The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. |
| 主权项 |
1. A pharmaceutically acceptable composition, comprising a compound of formula III, a pharmaceutically acceptable salt, a stereoisomer, or tautomer thereof and a pharmaceutically acceptable excipient; wherein: each of Z1 and Z2 is —OH; L1 is a covalent bond; Ring A is an optionally substituted phenyl ring where n is an integer between 0 and 4, inclusive, each occurrence of R1 is, independently, halogen, —OR, —CF3, —CN, —NO2, —NC, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R′)2, —CHO, —N3, —N2R, —N(R′)2, —B(OH2), or an optionally substituted C1-8 aliphatic group, each occurrence of R is hydrogen, an optionally substituted C1-6 aliphatic group, or an optionally substituted C6-12 aliphatic aryl group, at least one R1, if present, is in an ortho position relative to the boron atom, and each occurrence of R′ is hydrogen —C(O)R, a suitable amino protecting group, or an optionally substituted C1-6 aliphatic group, or optionally substituted C6-12 aryl group; X is —O—CH2—CH2—, —CH2—O—CH2—,—CH2—CH2—CH2—, —O—CH(CH3)—CH2—, —O—CH2—CH2—CH2—, —C(═O)—CH2—CH2—, —CH2—CH2—C(═O)—, —CH2—CH2—CH2—C(═O)—, or —(CCH3═N)—O—CH2— and X is in a para position relative to the boron atom; and Ring B is a phenyl ring where m is 0. |
